Accumulating evidence indicates that mutations in the human UGTJ gene locus abolish hepatic bilirubin UDP-glucuronosyltransferase activity and cause the subsequent accumulation of bilirubin to toxic levels in patients with Crigler-Najjar type 1 (CN-I). Genetic and biochemical criteria are required to link CN-I with mutations in UGTI. Here we present analysis of mutations at the UGTJ locus in three individuals that were clinically diagnosed with CN-I (two related and one unrelated). Each patient carries a single base substitution that alters conserved residues in the transferase enzyme molecule, serine to phenylalanine at codon 376 and glycine to glutamic acid at codon 309. Each was homozygous for the defect as demonstrated by sequencing and RFLPs. Mutant cDNAs, constructed by site-directed mutagenesis, inserted into expression vectors, and transfected into COS-1 cells, supported the synthesis of the bilirubin transferase protein but only cells transfected with the wild-type cDNA expressed bilirubin UDP-glucuronosyltransferase activity. The data provide conclusive evidence that alterations at Gly 309 and Ser 376 are the genetic basis for CN-I in these families. These results suggest that the two codons, located in conserved regions of the molecule, are part of the active site of the bilirubin enzyme. (J. Clin. Invest. 1994. 93:564-570.)
Introduction
Bilirubin, the product of heme degradation, is a potentially lethal endogenous substance when present at high levels in the blood. Bilirubin UDP-glucuronosyltransferase (UDPGT)'
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conjugates one, then often a second, glucuronic acid molecule to the carboxyl groups ofthe propionate side chains ofbilirubin (C-8 or C-12), making it polar and therefore readily excreted in the bile (1) . This enzyme is membrane bound, and its active site is located on the luminal side of the liver endoplasmic reticulum (2) . Bilirubin UDPGT activity is not detected in patients with the autosomal recessive disorder Crigler Najjar, type I (CN-I) (3) . Therefore, CN-I individuals have high serum bilirubin levels (at least 20 mg/dl; normal 0.2-1.2 mg/ dl) primarily unconjugated, which lead to deposition of bilirubin in the brain and nervous tissue. The majority of CN-I patients generally succumb in early childhood due to kernicterus (brain degeneration) (4) , yet some live to early adulthood either with the aid of phototherapy and sequestering drugs or because oflate onset ofthe disease. Liver transplantation which is now often performed on the CN-I patients may further extend life expectancy (5) . The less severe CN type II syndrome (6) is also characterized by high serum bilirubin levels of between 3 and 20 mg/dl, but is distinguishable from CN-I by the presence of detectable bilirubin glucuronidating activity (indicated by the presence of bilirubin glucuronides in the bile). The latter is often discernible only after treatment with phenobarbital, an inducer of hepatic bilirubin UDPGT activity (6) . A third type of unconjugated hyperbilirubinemia is Gilbert's syndrome (7) , which affects 6% ofthe population and exhibits bilirubin levels of0.8-3 mg/dl (two-to sixfold above normal).
Bilirubin UDPGT activity arises from a gene complex of unusual structure (8) located on human chromosome 2 (9) . (10) . In human liver, UGTIA mRNA is fourfold more abundant than that of UGTID, and transcription of Given the complexity of the locus, familial hyperbilirubinemias arising from defects in the enzymes coded by UGTI could have many different possible bases, including mutations affecting the transcription or processing of primary transcripts. However, the relationship between the bilirubin UDPGT transcription units UGTJA and UGTID suggests that mutations in one of the common exons are the most frequent cause for the complete loss of bilirubin UDPGT activity in patients with CN-I. This appears to be supported by the data so far available concerning sequence alterations in UGTI associated with CN-I. These alterations include a 13-base frameshift deletion in exon 2 (12) , and point mutations in exons 2 (13) and 3 (14) . For all ofthe mutations, especially in cases where the suspected mutation is a potentially silent mutation, both biochemical and genetic criteria are required to associate a given mutation in UGTI with the inactivation of bilirubin UDPGT and the onset of CN-I disease. Continued analysis of the molecular basis of CN-I in different patients should further our understanding of the structure-function relationships of the various transferases encoded by this gene.
To that end, we have analyzed the UGTI locus in two separate families with children clinically diagnosed with CN-I. Diagnosis was based on serum bilirubin levels of 30-41 mg/dl (primarily unconjugated) and the lack ofany significant reduction in blood levels of the heme derivative after phenobarbital administration. We hypothesized that the cause of the unconjugated hyperbilirubinemia in the affected children from both families was due to a genetic defect in one or more of the common exons of the bilirubin UDPGT gene. PCR amplification of genomic DNA and analysis of the subclones revealed mutations that affect residues that are highly conserved in bilirubin and other UDPGT isozymes, Gly 309 and Ser 376. Expression studies comparing the activities of wild-type and mutant cDNA-encoded proteins demonstrated that each mutation can independently abolish HUG-Br1 enzyme activity.
Methods
CN-I patient diagnoses and histories. N.H. is a 13-yr-old white female who was the product of a third cousin mating developed unconjugated hyperbilirubinemia on day 2 of life, reaching a level of 13 mg/dl 2 d later. Jaundice progressed, and total bilirubin reached 20 mg/dl by 5 yr of age, despite phototherapy and phenobarbital treatment. A liver biopsy did not reveal histologic abnormalities, and a presumed diagnosis ofCrigler-Najjar syndrome was made. Because ofa continued rise in unconjugated hyperbilirubinemia (40 mg/dl by 10 yr) and the continued absence of any neurological sequelae, liver transplantation was performed at 12.5 yr of age. Transplantation ofthe left lateral segment of her father's liver was unsuccessful, but a second partial liver transplantation from a cadaver donor was successful. The bilirubin levels fell precipitously, and she remains neurologically normal. There was no detectable bilirubin UDPGT activity in a sample of her liver obtained at the time of surgery (Odell, G., personal communication).
Her male first cousin, T.C., an 1 -yr-old white male whose parents were also consanguineous, developed early onset unconjugated hyperbilirubinemia, which reached a level of 1 1.7 Polymerase chain reaction and sequencing of UGTI common exons. Genomic DNA was isolated from blood samples of affected individuals and relatives in both families as described previously ( 12) . For the analysis of the common UGTJ exons 2-5 in the two unrelated families, two slightly differing strategies were used. The analysis of M.L. and her family was carried out using the strategy reported previously for the analysis of UGTI in CN-1 patient F.B., and five subclones of exon 2 derived from the genomic DNA of M.L. were sequenced ( 12 ) . For the analyses ofthe patients N.H. and T.C. and their families, at least six separate rounds of asymmetric PCR were followed by direct sequencing and used the primers described by Ritter et al. ( 12) . Briefly, the primer pairs, PXG3 with PXG4, PXG5 with PXG6, PXG7 with PXG8, and PXG9 with PXG 10, flank exons 2, 3, 4, and 5, respectively, in the intron regions. The 50-id asymmetric PCR reaction contained I ,ug of genomic DNA, a primer pair (10 pmol of the upstream primer and 500 pmol of the downstream primer), 10 mM Tris-HCI, pH 8.3, 50 mM KCI, 1.5 mM MgCl2, 0.001% (wt/vol) gelatin, 0.2 mM each dNTP, and 1.5 U ofDNA polymerase (Amplitaq; Cetus Corp., Emeryville, CA). The reaction mixtures were overlaid with 30 pi mineral oil, and were subjected to 25 cycles of 94°C for 1 min, 60°C for 1.5 min, and 72°C for 3 min with a final extension time of 30 min. Nondenaturing PAGE was used to confirm that the correct size PCR product was made. The DNA was separated from primers and unincorporated nucleotides by chromatography on a I00-M1 bed of Sephacryl S-300 (Pharmacia LKB Biotechnology Inc., Piscataway, NJ), which was equilibrated with 10 mM Tris-HCI, pH 7.6, and 0.1 mM EDTA, and then was centrifuged twice at 1,700 g for 2 min. The double-stranded DNA concentration of the eluent was measured by fluorometry. Dideoxy DNA sequencing was done using the TaQuence kit (United States Biochemical Corp., Cleveland, OH). A modification of the protocol using the thermal cycler was carried out ( 15 ) . The samples were electrophoresed on a 6% sequencing gel that was fixed in 15% methanol and 5% acetic acid, dried, and exposed to x-ray film. We sequenced both strands of the DNA and compared the sequence to the published human bilirubin UDPGT cDNA sequence (10 The reaction mixtures were centrifuged for 10 min, and the supernatant was dried in a lyophilizer in the dark. A 30-M' aliquot ofchloroform was added to the dried supernatant and was applied to the bottom of a precoated silica gel preparative TLC plate (Pierce Chemical Co., Rockford, IL). The TLC plate was developed ( 17) , and then the dried plates were analyzed for activity by colorimetric observation (Radioanalytical Imaging Mark II system; AMBIS, Inc., San Diego, CA) before exposure to x-ray film.
Immunoprecipitation ofnewly synthesized protein in COS-J cells. Radiolabeling ofnewly synthesized protein in COS-I cells was followed by a single antibody immunoprecipitation. COS-l cells were transfected as described above and were incubated 3 d. During the last 5 h of culture, the cells were treated as follows. Starving media (3 ml/25 cm2 flask) without methionine were added, and cells were incubated for 1 h at 37°C. Labeling media (1 ml/flask) with [355Jmethionine, penicillin/streptomycin, and glutamine were added, and cells were shaken every 20 min for 3-4 h. Labeling was stopped by the addition of 50 Ml/flask of 10 mg/ml of cold methionine, 10 Ml of 50 mg/ml trypsin inhibitor, and 1 ml oflysis solution (1% Triton X-100, 0.5% Na-deoxy- (Fig. 1) .
The affected individual from the second family, M.L., had a normal sequence for exons 3, 4, and 5, but her exon 2 had a G --A base change at the second position of codon 309 (Fig.   1 ). This mutation is located 55 bases from the exon 2/intron 2 junction.
A single restriction site for NlaIV (GGNNCC) in the exon 4 PCR product is abolished by the C -T mutation and the resulting sequence, GGTTTC. ing to the wild-type allele yields a 224-and a 83-bp fragment when digested with NlaIV. The 309-bp PCR product made from a mutant allele is not digested with this enzyme. Therefore, carriers possess the 309-bp fragment from the mutant allele and the 224-bp fragment from the normal allele. DNA from the family of N.H. and T.C. were screened using the RFLP technique (Fig. 2) . From this analysis, it is clear that both sets of parents were carriers as were the paternal grandfather of N.H., and the paternal grandfather and the maternal grandmother of T.C. This pattern is the expected result if the C --T change is coinherited with the disease. There was no DNA available for the maternal grandparents of N.H.
The G --A mutation in the second family is predicted to eliminate a restriction site for the enzyme Sau3AI (GATC to AATC). Normal DNA corresponding to a 311-bp fragment, CN which encompasses exon 2 and is amplified by the primers PXG3 and PXG4, is digested at one site by Sau3AI, yielding two fragments of 183-and 128-bp (Fig. 3) . The mutant allele is predicted to lack the Sau3AI site. Fig. 3 shows the results of a Sau3AI analysis of DNA of the proband M.L. and her family.
The results indicate that M.L. is a homozygote for the G -* A base change at codon 309, whereas her parents and one sibling (sibling 2 in Fig. 3 ) are heterozygotic. The remaining sibling (sibling 1) is homozygous for the normal allele.
To determine whether the alterations in the UGTI gene lead to alterations in enzyme activity, we constructed mutant HUG-Brl expression plasmids containing either the C T mutation at codon 376 (pHUG-Brl-Phe376) or the G A mutation at codon 309 (pHUG-Brl-Glu309). pHUG-BrlPhe376 and pHUG-Brl-Glu309 are identical to the normal HUG-Brl expression unit, pHUG-Brl (10), with the exception of the designated single base substitution. For controls, constructs with the orientation of insert reversed with respect to the SV40 promoter were used. The normal pHUG-BrI unit or mutant expression constructs were transfected into COS-1 cells. Bilirubin UDPGT activity was detectable in either human microsomes or homogenates of COS-1 cells transfected with the wild-type pHUG-Brl expression plasmid. For the pHUG-Brl-transfected cells, activity was higher when the assay was performed at pH 6.4 than at pH 7.6 (Ritter, J. K., M. Yeatman, C. Kaiser, and I. S. Owens, manuscript submitted for publication). No expression ofactivity was detected in cells transfected with pHUG-Brl-Phe376 and pHUG-Brl-Glu309, regardless of the orientation of the cDNA or the pH (Fig. 4) .
If the alteration destabilizes the protein, then the lack of enzyme activities could be because ofa lack ofenzyme protein. Alternatively, the mutation could affect the ability of the enzyme to carry out the glucuronidation of bilirubin without altering protein levels. To distinguish between these two possibilities, transfected COS-1 cells were grown in radiolabeled media, and bilirubin UDPGT protein was immunocomplexed and was trapped with protein A-Sepharose (Sigma Immunochemicals, St. Louis, MO). The same size and amount of the protein was produced in cells with normal or mutant HUG-Brl cDNA in the correct orientation (Fig. 5) . No protein was synthesized in cells that were transfected with the expression plasmids containing the mutant cDNAs in the reverse orientation (Fig. 5) . .f tion in the cDNA alone abolishes enzyme activity when expressed in cell culture. In addition, we have identified a second, different point mutation in an unrelated CN-1 patient, M.L., which results in the substitution of a glutamic acid residue for glycine at position 309 of the HUG-Br 1-encoded bilirubin isozyme, also resulting in inactivation of enzyme activity.
RFLPs associated with each mutation permitted an analysis of the family for inheritance patterns of the affected allele. Before pursuing the bilirubin activity assays, we were able to determine by the inheritance pattern of both RFLPs that each defect was a candidate for the cause of CN-1. In the first family, an NlaIV RFLP allowed us to rapidly screen the DNA from blood samples of the extended family (30 individuals). In the second family, a Sau3AI RFLP allowed us to identify one of her siblings as a carrier. The NlaIV and Sau3AI RFLPs can be used for screening the respective families to identify carriers of the defect.
Extrapolation ofthe results with the COS-I cells transfected with the mutant HUG-Br 1 expression constructs containing the C -* T or G --A mutations at codons 376 and 309, respectively, to the in vivo situation suggests that these alterations are the cause of CN-I in N.H. and T.C. in the first family and M.L. in the second family. The activity of the other bilirubin UDPGT isoform, HUG-Br2, is likely affected as well since it has identical sequence in exons 2-5. This is supported by the fact that HUG-Br2 is inducible by phenobarbital ( 10) , and these patients did not respond to oral phenobarbital administration. The activities of the two phenol UDPGT isoforms expressed at this locus are also presumed to be affected by the location of the mutations in the common exons for these enzymes. Indeed, N.H. has been shown to have reduced hepatic microsomal activity toward 4-nitrophenol and 4-methylumbelliferone ( 13) . A partial rather than complete loss of phenol glucuronidating activities in N.H. is due to the existence of other UDPGT genes at unlinked loci that encode isoforms active towards phenolic substrates, possibly the testosterone isoform ( 19) .
Both of the point mutations are predicted to result in the alteration of highly conserved residues in the protein sequence of the HUG-Br 1 -encoded (and other UGT 1-encoded) isoform(s). The C -> T base change at the second position of codon 376 in HUG-Brl results in a nonconservative substitution of phenylalanine for a serine. This serine codon is conserved in four rat UDPGT genes (three steroid and the bilirubin/phenol UDPGT gene), and the mouse bilirubin/phenol UDPGT gene. The small polar serine is replaced by a small nonpolar alanine in three other rat UDPGTs and one other mouse UDPGT (data not shown). This suggests the need for a small amino acid residue at position 376 of HUG-Brl rather than a large, bulky, hydrophobic residue, like phenylalanine. The glycine at position 309 is absolutely conserved in all UDPGT sequences reported to date. It is part ofa larger, highly conserved domain extending from positions 298-315, represented by the sequence Ser-Gly-(Glu/Asp)-(His/Asn)-Gly-(Ile/ Val ) -Val-Val-Phe-Ser-Leu-Gly-Ser-Met-( Val/Ile)-Ser-(Glu/Asn)-(Ile/Met) (GenBank M84122). At least 95% conservation is observed in the identity of these 18 amino acids in the bilirubin/phenol or steroid UDPGTs reported so far in the GenBank/EMBL database for the rat, mouse, or human. Its function is unknown.
In the transferases produced by UGTI, exons 2-5 are believed to encode the UDPGA binding site. This carboxyl terminus is highly conserved across species in that the rat and human bilirubin UDPGT isoforms are 90% identical (10) . The active site residues in the bilirubin UDPGT enzymes are not yet known. However, chimeric studies show that the catalytic site in two human bile acid/steroid UDPGTs have nine amino acid residues between 385 and 469 which are important for catalytic efficiency (20) . This may correspond to a similar active site region in bilirubin UDPGT including Ser376.
The UGTI locus encodes transferases which glucuronidate various aglycone substrates. CN-1 patients possess a variety of phenotypes for deficiencies in glucuronidation of these substrates (21 ). We now know this is because of a variety of mutations in different families (22) . Our study, for the first time, shows regions of the bilirubin transferase molecule that are critical for activity and, therefore, are likely to be part of the active site of the isoform. Further observations of new mutations along with the corresponding phenotype may help us to uncover other critical amino acid residues at this gene locus.
